Search Results - "Mehta, Amitkumar"

PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD by Haverkos, Bradley M., Abbott, Diana, Hamadani, Mehdi, Armand, Philippe, Flowers, Mary E., Merryman, Reid, Kamdar, Manali, Kanate, Abraham Sebastian, Saad, Ayman, Mehta, Amitkumar, Ganguly, Siddhartha, Fenske, Timothy S., Hari, Parameswaran, Lowsky, Robert, Andritsos, Leslie, Jagasia, Madan, Bashey, Asad, Brown, Stacey, Bachanova, Veronika, Stephens, Deborah, Mineishi, Shin, Nakamura, Ryotaro, Chen, Yi-Bin, Blazar, Bruce R., Gutman, Jonathan, Devine, Steven M.

“…Given the limited treatment options for relapsed lymphoma post–allogeneic hematopoietic cell transplantation (post–allo-HCT) and the success of programmed…”
Get full text

Transcriptional determinants of cancer immunotherapy response and resistance by Gupta, Romi, Mehta, Amitkumar, Wajapeyee, Narendra

“…The host immune response is a potent defense mechanism against cancer development and progression. To survive, cancer cells must develop mechanisms to evade…”
Get more information

Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models by Ng, Samuel Y., Yoshida, Noriaki, Christie, Amanda L., Ghandi, Mahmoud, Dharia, Neekesh V., Dempster, Joshua, Murakami, Mark, Shigemori, Kay, Morrow, Sara N., Van Scoyk, Alexandria, Cordero, Nicolas A., Stevenson, Kristen E., Puligandla, Maneka, Haas, Brian, Lo, Christopher, Meyers, Robin, Gao, Galen, Cherniack, Andrew, Louissaint, Abner, Nardi, Valentina, Thorner, Aaron R., Long, Henry, Qiu, Xintao, Morgan, Elizabeth A., Dorfman, David M., Fiore, Danilo, Jang, Julie, Epstein, Alan L., Dogan, Ahmet, Zhang, Yanming, Horwitz, Steven M., Jacobsen, Eric D., Santiago, Solimar, Ren, Jian-Guo, Guerlavais, Vincent, Annis, D. Allen, Aivado, Manuel, Saleh, Mansoor N., Mehta, Amitkumar, Tsherniak, Aviad, Root, David, Vazquez, Francisca, Hahn, William C., Inghirami, Giorgio, Aster, Jon C., Weinstock, David M., Koch, Raphael

“…T- and NK-cell lymphomas (TCL) are a heterogenous group of lymphoid malignancies with poor prognosis. In contrast to B-cell and myeloid malignancies, there are…”
Get full text

Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study by Flowers, Christopher R, Matasar, Matthew J, Herrera, Alex F, Hertzberg, Mark, Assouline, Sarit, Demeter, Judit, McMillan, Andrew, Mehta, Amitkumar, Opat, Stephen, Trnňný, Marek, Musick, Lisa, Hirata, Jamie, Yang, Annie, Sehn, Laurie H

“…Follicular lymphoma (FL) is the most common type of indolent non-Hodgkin lymphoma. Despite treatment advances that have improved outcomes for patients with…”
Get full text

Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor by Alkharabsheh, Omar, Alsayed, Alhareth, Morlote, Diana M, Mehta, Amitkumar

“…Bruton tyrosine kinase (BTK) inhibitors have become an important therapy for untreated and previously treated patients with chronic lymphocytic leukemia (CLL)…”
Get full text

Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial by Morschhauser, Franck, Ghosh, Nilanjan, Lossos, Izidore S., Palomba, M. Lia, Mehta, Amitkumar, Casasnovas, Olivier, Stevens, Don, Katakam, Sudhakar, Knapp, Andrea, Nielsen, Tina, McCord, Ron, Salles, Gilles

“…We evaluated the triplet regimen obinutuzumab-atezolizumab-lenalidomide (G-atezo-len) for patients with relapsed/refractory (R/R) follicular lymphoma (FL) in…”
Get full text

Treatment approaches of hard-to-treat non-Hodgkin lymphomas by Nandagopal, Lakshminarayanan, Mehta, Amitkumar

“…Even after recent advancements with monoclonal antibodies, antibody drug conjugates and immune therapies, relapsed and refractory lymphomas remain challenging…”
Get more information

Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study by Qin, Kai, Honjo, Kazuhito, Sherrill-Mix, Scott, Liu, Weimin, Stoltz, Regina M, Oman, Allisa K, Hall, Lucinda A, Li, Ran, Sterrett, Sarah, Frederick, Ellen R, Lancaster, Jeffrey R, Narkhede, Mayur, Mehta, Amitkumar, Ogunsile, Foluso J, Patel, Rima B, Ketas, Thomas J, Cruz Portillo, Victor M, Cupo, Albert, Larimer, Benjamin M, Bansal, Anju, Goepfert, Paul A, Hahn, Beatrice H, Davis, Randall S

“…Patients with chronic lymphocytic leukemia (CLL) have reduced seroconversion rates and lower binding antibody (Ab) and neutralizing antibody (NAb) titers than…”
Get full text

Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas by Coveler, Andrew L, Smith, David C, Phillips, Tycel, Curti, Brendan D, Goel, Sanjay, Mehta, Amitkumar N, Kuzel, Timothy M, Markovic, Svetomir N, Rixe, Olivier, Bajor, David L, Gajewski, Thomas F, Gutierrez, Martin, Lee, Hun Ju, Gopal, Ajay K, Caimi, Paolo, Heath, Elisabeth I, Thompson, John A, Ansari, Sahar, Jacquemont, Celine, Topletz-Erickson, Ariel, Zhou, Peigen, Schmitt, Michael W, Grilley-Olson, Juneko E

“…BackgroundSEA-CD40 is an investigational, non-fucosylated, humanized monoclonal IgG1 antibody that activates CD40, an immune-activating tumor necrosis factor…”
Get full text

Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium by Vose, Julie M, Fu, Kai, Wang, Lu, Mansoor, Adnan, Stewart, Douglas, Cheng, Hongxia, Smith, Lynette, Yuan, Ji, Qureishi, Hina Naushad, Link, Brian K, Cessna, Melissa H, Barr, Paul M, Kahl, Brad S, Mckinney, Matthew S, Khan, Nadia, Advani, Ranjana H, Martin, Peter, Goy, Andre H, Phillips, Tycel J, Mehta, Amitkumar, Kamdar, Manali, Crump, Michael, Pro, Barbara, Flowers, Christopher R, Jacobson, Caron A, Smith, Sonali M, Stephens, Deborah M, Bachanova, Veronika, Jin, Zhaohui, Wu, Shishou, Hernandez-Ilizaliturri, Francisco, Torka, Pallawi, Anampa-Guzmán, Andrea, Kashef, Farshid, Li, Xing, Sharma, Sunandini, Greiner, Timothy C, Armitage, James O, Lunning, Matthew, Weisenburger, Dennis D, Bociek, Robert G, Iqbal, Javeed, Yu, Guohua, Bi, Chengfeng

“…Patients with mantle cell lymphoma (MCL) exhibit a wide variation in clinical presentation and outcome. However, the commonly used prognostic models are…”
Get full text

High Throughput Kinomic Profiling of Human Clear Cell Renal Cell Carcinoma Identifies Kinase Activity Dependent Molecular Subtypes by Anderson, Joshua C, Willey, Christopher D, Mehta, Amitkumar, Welaya, Karim, Chen, Dongquan, Duarte, Christine W, Ghatalia, Pooja, Arafat, Waleed, Madan, Ankit, Sudarshan, Sunil, Naik, Gurudatta, Grizzle, William E, Choueiri, Toni K, Sonpavde, Guru

“…Despite the widespread use of kinase-targeted agents in clear cell renal cell carcinoma (CC-RCC), comprehensive kinase activity evaluation (kinomic profiling)…”
Get full text

P105 NEX-T CD19 chimeric antigen receptor (CAR) T-cell therapy CC-97540 (BMS-986353): Preclinical and translational evidence of deep B-cell depletion suitable for study in severe refractory autoimmune diseases by Schett, Georg, Feldman, Tatyana, Abramson, Jeremy, Hu, Boyu, Müller, Fabien, Koegel, Ashley, Thorpe, Jerill, Salmon, Ruth, Wu, Fan, Varun, Divya, Maier, Alison, Kugler, David, Westoby, Matthew, Delev, Nikolay, Mehta, Amitkumar

“…ObjectiveCC-97540 (BMS-986353) is an investigational CD19 CAR T-cell therapy utilizing the lisocabtagene maraleucel CD19-directed CAR T construct with a 41BB…”
Get full text

The impact of structural factors on diagnostic delay in diffuse large B‐cell lymphoma by Zurko, Joanna C., Wade, Raymond C., Mehta, Amitkumar

“…Background Reducing diagnostic delays in cancer has been a major interest worldwide; however, the literature on diagnostic delays in lymphoma remains scarce…”
Get full text

A nomogram including baseline prognostic factors to estimate the activity of second‐line therapy for advanced urothelial carcinoma by Pond, Gregory R., Agarwal, Neeraj, Bellmunt, Joaquim, Choueiri, Toni K., Qu, Angela, Fougeray, Ronan, Vaughn, David, James, Nicholas D., Salhi, Yacine, Albers, Peter, Niegisch, Günter, Galsky, Matthew D., Wong, Yu‐Ning, Ko, Yoo‐Joung, Stadler, Walter M., O'Donnell, Peter H., Sridhar, Srikala S., Vogelzang, Nicholas J., Necchi, Andrea, Di Lorenzo, Giuseppe, Sternberg, Cora N., Mehta, Amitkumar, Sonpavde, Guru

“…Objective To study the impact of the prognostic factors liver metastasis (LM), anaemia (haemoglobin [Hb] <10 g/dL), Eastern Cooperative Oncology Group…”
Get full text

Association of Immune-Mediated Cerebellitis With Immune Checkpoint Inhibitor Therapy by Zurko, Joanna, Mehta, Amitkumar

“…Immune-mediated encephalitis related to immune checkpoint inhibitor therapy is a rare but increasingly described condition that can cause significant…”
Get full text

474 Phase 1 study of SEA-TGT, a human, nonfucosylated anti-TIGIT monoclonal antibody with enhanced immune-effector function, in patients with advanced malignancies (SGNTGT-001, trial in progress) by Davar, Diwakar, Ribrag, Vincent, Sarkozy, Clementine, Garralda, Elena, Oberoi, Honey Kumar, Mehta, Amitkumar, Curigliano, Giuseppe, Belli, Carmen, Zain, Jasmine, Herrera, Alex, Sanborn, Rachel, Dumbrava, Ecaterina, Forero-Torres, Andres, Ansell, Stephen

“…BackgroundT-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory domains (TIGIT), and costimulatory receptor CD226…”
Get full text

How Do I Recommend Extended Adjuvant Hormonal Therapy? by Mehta, Amitkumar, Carpenter, John T.

“…Opinion statement Estrogen-dependent growth of some breast cancers was a key observation, which led to the development of tamoxifen and aromatase inhibitors…”
Get full text

Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma by Agarwal, Neeraj, Bellmunt, Joaquim, Maughan, Benjamin L, Boucher, Kenneth M, Choueiri, Toni K, Qu, Angela Q, Vogelzang, Nicholas J, Fougeray, Ronan, Niegisch, Guenter, Albers, Peter, Wong, Yu-Ning, Ko, Yoo-Joung, Sridhar, Srikala S, Tantravahi, Srinivas K, Galsky, Matthew D, Petrylak, Daniel P, Vaishampayan, Ulka N, Mehta, Amitkumar N, Beer, Tomasz M, Sternberg, Cora. N, Rosenberg, Jonathan E, Sonpavde, Guru

“…Micro-Abstract This study examined the association of progression-free survival at 6 months with overall survival in the context of second-line therapy of…”
Get full text

Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy by Pond, Gregory R., Ph.D., P.Stat, Di Lorenzo, Giuseppe, M.D, Necchi, Andrea, M.D, Eigl, Bernhard J., M.D, Kolinsky, Michael P., M.D, Chacko, Raju T., M.D, Dorff, Tanya B., M.D, Harshman, Lauren C., M.D, Milowsky, Matthew I., M.D, Lee, Richard J., M.D, Galsky, Matthew D., M.D, Federico, Piera, M.D, Bolger, Graeme, M.D, DeShazo, Mollie, M.D, Mehta, Amitkumar, M.D, Goyal, Jatinder, M.D, Sonpavde, Guru, M.D

“…Abstract Background Prognostic factors in men with penile squamous cell carcinoma (PSCC) receiving systemic therapy are unknown. A prognostic classification…”
Get full text

Heparin Induced Thrombocytopenia-Our Three Years Experience at a Community Hospital by Mehta, Amitkumar, MD, Gupta, Sachin, MD, Bustos, Francis, BS, Jamshidi, Aria, BS, Shibli, Muhammad, MD

Get full text